News Lilly’s Taltz scrapes win against Humira in psoriatic arthri... Eli Lilly’s Taltz has beaten AbbVie’s blockbuster Humira in a psoriatic arthritis study involving patients who hadn’t been treated before with a disease-modifying drug, but only just.
News Amid tough competition, Novartis makes case for rheumatology... Swiss pharma hopes to bounce back from Q1 sales disappointment
News Novartis tests Cosentyx against Humira and biosimilars Trials will cover psoriatic arthritis and ankylosing spondylitis
News Pfizer's Xeljanz approved in psoriatic arthritis Xeljanz is first JAK inhibitor approved in psoriatic arthritis
Sales & Marketing Biotech is back, with Craig Ackerman In Philadelphia this month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
